医学
二尖瓣反流
经皮
心脏病学
二尖瓣
内科学
二尖瓣修补术
瓣膜性心脏病
二尖瓣环成形术
二尖瓣置换术
食品药品监督管理局
外科
环境卫生
作者
Diana Khatib,Peter J. Neuburger,Sabrina Pan,Lisa Q. Rong
标识
DOI:10.1053/j.jvca.2022.05.005
摘要
Significant mitral regurgitation (MR) is the most common valvular disease in the United States in patients older than 75. However, many patients with severe MR are at a high risk for surgical repair due to other significant comorbidities. Over the past decade, many transcatheter mitral valve devices have been studied that address the different mechanisms of MR, but only a few have received a Conformité Européene (CE) mark or United States Food and Drug Administration (FDA) approval. The Carillon, Cardioband, and Mitralign all received CE marking for percutaneous mitral annuloplasty, while the Tendyne and SAPIEN 3 received a CE mark and FDA approval, respectively, for transcatheter mitral valve replacement. Finally, the NeoChord DS 1000 received a CE mark for transcatheter chordal repair. Each of these devices is reviewed in detail, including device indications, performance in clinical trials, anesthetic management, intraprocedural imaging guidance, and postprocedural complications. Although percutaneous devices will appear and disappear from use, understanding the procedural considerations remains highly relevant, as these key principles will apply to the next generation of transcatheter valve interventions.
科研通智能强力驱动
Strongly Powered by AbleSci AI